Novartis reshapes research, closes some Swiss, Chinese units

By John Miller ZURICH (Reuters) – Novartis is closing some of its research operations in Switzerland and China and cutting 175 jobs, part of the Swiss drug maker’s effort to centralize control over its drug discovery programs and contain costs. Novartis, which employs 120,000 globally, is also relocating its tropical disease research arm from Singapore to California. The Basel-based company is consolidating research oversight within its Swiss headquarters and the Novartis Institutes for Biomedical Research (NIBR) near Boston, now headed by Jay Bradner.

Excerpt from:
Novartis reshapes research, closes some Swiss, Chinese units